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Follicular lymphoma (FL) is the most frequent indolent lymphoma, accounting for approximately 20-40% of all nonHodgkin lymphomas. 1 It constitutes a distinct lymphoma entity in the WHO classification of hematologic neoplasms and is characterized by the proliferation of CD10( þ ) follicular center B-cells and by a specific chromosomal translocation, t(14;18) (q32;q21), which is present in approximately 80% of all cases. 1 However, approximately 15-20% FL are known to lack t(14;18).
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Figure 1
Differences of genomic alterations between t(14;18) positive and negative groups. (a) Genome-wide frequency of genomic imbalance in the t(14;18) positive and negative groups. Trisomy 3 (arrows) is only found in the t(14;18) negative group. The average number of genomic copy number regions of gain and loss in the t(14;18) negative group was higher than that in the t(14;18) positive group. The average number of gain and loss in t(14;18) positive cases was 2.3 and 2.2 regions/case respectively; the average number of gain and loss regions in t(14;18) negative cases was 4.1 and 3.7 regions/case, respectively. (b) A representative individual genome profile of FL with trisomy 3 (case no. Q5470). (c) Dual-color FISH analysis for 3q gain and 18q gain of case no. Q5470 with trisomies 3 and 18.
Previously, Jardin et al. (2002) reported that FL without t(14;18) and with BCL6 rearrangement is a distinct subtype. 4 Horsman et al. (2003) investigated the cytogenetic aberrations of t(14;18) negative FL and found that the cases showing chromosome 18 duplication and BCL2-protein expression may comprise a unique subgroup of FL. 3 Recently, Guo et al. (2005) reported that the t(14;18) positive group is a single tumor entity, most of which is accounted for by grades 1 and 2, whereas t(14;18) negative-FL was found to consist of distinct subgroups, majority of which is accounted for by grades 3. 5 These reports suggest that t(14;18) negative FL comprise distinct subtypes.
To clarify the molecular cytogenetic mechanism of t(14;18) negative FL, we performed a high-resolution BAC array CGH (1.3-mega base resolution, 2304 BAC/PAC clone/whole genome) 6 for 24 of t(14:18) negative and 56 of t(14;18) positive cases. Presence or absence of BCL6 rearrangement was also confirmed for all the cases (Table 1) . Lymph node samples (80 FL cases), paraffin-embedded specimens, DNA samples and clinical data were obtained from Fukuoka University and Aichi Cancer Center with the institutional review boards of both these institutions approving the protocol. All DNA samples were obtained from the lymph node at the time of diagnosis before any treatment being administered. FL was diagnosed and subclassified to grade 1-3B from the morphological findings according to the definition of the WHO classification of malignant lymphomas by three expert hematopathologists (NS, KM and OK).
As shown in Figure 1 , gains of 1q, 3, 7p, 7q, 18 and losses of 1p36, 6q and 9p21.3 were frequent genomic aberrations in the t(14;18) negative group. Gains of 7p, 12q and 18p-q21 and a loss of 1p36 were frequently detected in the t(14;18) positive group. Of these frequent genomic alterations, gain of chromosome 3/trisomy 3 and gain/amplification of 18q21-qtel (BCL2) and loss of 9p21 (p16 INK4a locus) were significantly frequently detected in the group of t(14;18) negative (Fisher's Po0.05) ( Table 2) . Number of patients whose data were available. c Paraffin sections from each sample were immunostained with monoclonal antibodies against CD10 (Novocastra, Newcastle, UK), Bcl2 (DAKO, Carpinteria, CA, USA), MUM1 (DAKO), BCl6 (Novocastra). d FISH for translocation of 3q27 was performed for all 80 cases; the LSI IGH/Bcl6 Dual Color, Dual Fusion Translocation Probe (Vysis) probe set was used. Southern blot analysis for 3q27 translocation, using a probe including the major translocation cluster region (4.0 kb), was performed for 53 cases, which comprises 24 t(14;18) negative and 29 t(14;18) positive cases. Six of the t(14;18) negative cases (grade 3A: 4, grade 3B: 2) and four of t(14;18) positive cases (grades 1 and 2) showed BCL6 rearrangement. An important finding is that trisomy 3 (gain of chromosome 3) was observed in 38% of the t(14;18) negative group (nine cases), whereas this gain was not observed in the t(14;18) positive group. Majority of the cases with trisomy 3 showed CD10(À)MUM1( þ ) (7 of the 9 cases; 78%), while FL without trisomy 3 cases infrequently showed MUM1 expression (3 of 52 examined cases). None of the cases with trisomy 3 possessed the 3q27 translocation. Furthermore, our data imply that translocation of 3q27 and trisomy 3 are mutually exclusive.
Significant differences between t(14;18) negative and positive groups were also recognized in the frequencies of genomic gain/ amplification of 18q21-qtel, which includes BCL2 but not MALT1. The frequency of the 18q21 gain/amplification in the t(14;18) negative group (nine cases, 38%) was significantly higher than that of the t(14;18) positive group (five cases, 10%; Fisher's P ¼ 0.004). In the t(14;18) negative group, eight cases registered BCL2 protein expression. The majority of cases with 18q gain/amplification featured BCL2 protein expression (7 of 9 cases), while cases lacking 18q gain/amplification showed almost no BCL2 protein expression (1 of 15 cases) ( Table 2 ). These results suggest that, in t(14;18) negative cases, the gain/ amplification of chromosome 18 is linked to an aberrant BCL2 protein expression. Furthermore, in the t(14;18) negative group, eight of the nine cases showing trisomy 3 also represented gain/ amplification of chromosome 18, whereas only one case out of remaining 15 cases without trisomy 3 represented 18q gain/ amplification (Fisher's Po0.0001).
We have recently reported a distinct subtype of FL representing CD10(À)MUM1( þ ), grades 3A and B morphology, diffuse proliferation, lack of t(14;18) negative, while they exhibited follicular structure with follicular dendritic meshwork, and a high rate of somatic hypermutation and ongoing mutation. 7 In this study, we further demonstrated that most of CD10(À)MUM1( þ ) cases (10 of 80 cases) showed chromosome 3 abnormality such as a trisomy 3 (seven cases) or a 3q27 translocation (two cases). CD10 is a marker for germinal center (GC) B cell, and thus its expression suggests that GC B cells are normal counterpart of FL. MUM1/IRF4 is a lymphoidspecific member of the interferon regulatory factor family of transcription factor and it is a reliable marker of late stage-GC or post-GC B cells. 8 As majority of FL with trisomy 3 represents CD10(À) MUM1( þ ), FL with trisomy 3 might be derived from the 'late-stage' GC but not from the 'early-stage GC' and 'post-GC' B cell.
In summary, FL with trisomy 3 is genomically characterized by t(14;18) negative, gain/amplification of 18/18q, and a high frequency of loss of 9p21.3 (p16 INK4a locus), and is immunophenotypically characterized by CD10(À)MUM1( þ ), suggesting that the subtype may be derived from late germinal center B-cells.
